Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert W Akita

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Seminars in Oncology|July 4, 2003
Preclinical studies with Erlotinib (Tarceva)Robert W Akita, Mark X Sliwkowski
The Journal of Biological Chemistry|May 10, 2002
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent associationElicia Penuel, Robert W Akita, Mark X Sliwkowski
Cancer Research|February 7, 2007
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expressionGabriele Schaefer, Lihua Shao, Klara Totpal, et al.
Nature Communications|September 8, 2016
High cell-surface density of HER2 deforms cell membranesInhee Chung, Mike Reichelt, Lily Shao, et al.
Cancer Cell|May 5, 2009
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Teemu T Junttila, Robert W Akita, Kathryn Parsons, et al.
Cancer Cell|September 3, 2002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthDavid B Agus, Robert W Akita, William D Fox, et al.
Cancer Research|October 20, 2017
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug ConjugatesNiña G Caculitan, Josefa Dela Cruz Chuh, Yong Ma, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Seminars in Oncology|July 4, 2003
Preclinical studies with Erlotinib (Tarceva)Robert W Akita, Mark X Sliwkowski
The Journal of Biological Chemistry|May 10, 2002
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent associationElicia Penuel, Robert W Akita, Mark X Sliwkowski
Cancer Research|February 7, 2007
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expressionGabriele Schaefer, Lihua Shao, Klara Totpal, et al.
Nature Communications|September 8, 2016
High cell-surface density of HER2 deforms cell membranesInhee Chung, Mike Reichelt, Lily Shao, et al.
Cancer Cell|May 5, 2009
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Teemu T Junttila, Robert W Akita, Kathryn Parsons, et al.
Cancer Cell|September 3, 2002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthDavid B Agus, Robert W Akita, William D Fox, et al.
Cancer Research|October 20, 2017
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug ConjugatesNiña G Caculitan, Josefa Dela Cruz Chuh, Yong Ma, et al.
Pageof 1